Anti-Tuberculosis Therapeutics Market 2027 by Drug Class, End User and Geography | The Insight Partners

Anti-Tuberculosis Therapeutics Market Forecast to 2027 - Covid-19 Impact and Global Analysis - By Drug Class (Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Fluoroquinolones, Aminoglycosides, Others); End User (Hospitals & Clinics, Government Agencies, Non Profit Organizations, Others) and Geography

Report Code: TIPRE00008533 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

Tuberculosis (TB) treatment is completed over a long period, and constant medicine and monitoring is needed during the treatment. This eventually results in complete high treatment costs. Increasing prevalence of pediatric tuberculosis and growing incidence of multi-drug-resistant tuberculosis (MDR TB) and extensively drug-resistant (XDR) TB incidences are more driving the growth of the market.

MARKET DYNAMICS

The anti-tuberculosis therapeutics market is projected to grow in the forecast period owing to growing prevalence of tuberculosis, rising government initiative for tuberculosis awareness, increasing healthcare expenditure and developed diagnostic strategies. Moreover, the upsurge in number of hospitals and clinics for TB is also offering opportunities in market growth during the forecast period.

MARKET SCOPE

The "Global Anti-Tuberculosis Therapeutics Market Analysis to 2027" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of anti-tuberculosis therapeutics market with detailed market segmentation by drug class, end user and geography. The global anti-tuberculosis therapeutics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Anti-tuberculosis therapeutics market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The global anti-tuberculosis therapeutics market is segmented on the basis of drug class and end user. Based on drug class, the market is segmented into isoniazid, rifampin, ethambutol, pyrazinamide, fluoroquinolones, aminoglycosides, and others. Based on end user, the anti-tuberculosis therapeutics market is segmented into hospitals & clinics, government agencies, non profit organizations, and others.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global anti-tuberculosis therapeutics market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The anti-tuberculosis therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting anti-tuberculosis therapeutics market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the anti-tuberculosis therapeutics market in these regions.




Get more information on this report :

MARKET PLAYERS


The report covers key developments in the Anti-tuberculosis therapeutics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Anti-tuberculosis therapeutics market are anticipated to lucrative growth opportunities in the future with the rising demand for Anti-tuberculosis therapeutics market in the global market. Below mentioned is the list of few companies engaged in the Anti-tuberculosis therapeutics market.

The report also includes the profiles of key Anti-tuberculosis therapeutics market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

- Macleods Pharmaceuticals Ltd.
- Otsuka Pharmaceutical Co., Ltd.
- Johnson & Johnson Services, Inc.
- Pfizer Inc.
- LUPIN
- Novartis AG
- AstraZeneca PLC
- Eli Lilly And Company
- GlaxoSmithKline Plc.
- Sanofi

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Anti-Tuberculosis Therapeutics Market - By Drug Class
1.3.2 Anti-Tuberculosis Therapeutics Market - By End User
1.3.3 Anti-Tuberculosis Therapeutics Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ANTI-TUBERCULOSIS THERAPEUTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ANTI-TUBERCULOSIS THERAPEUTICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. ANTI-TUBERCULOSIS THERAPEUTICS MARKET - GLOBAL MARKET ANALYSIS
6.1. ANTI-TUBERCULOSIS THERAPEUTICS - GLOBAL MARKET OVERVIEW
6.2. ANTI-TUBERCULOSIS THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. ANTI-TUBERCULOSIS THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. ISONIAZID
7.3.1. Overview
7.3.2. Isoniazid Market Forecast and Analysis
7.4. RIFAMPIN
7.4.1. Overview
7.4.2. Rifampin Market Forecast and Analysis
7.5. ETHAMBUTOL
7.5.1. Overview
7.5.2. Ethambutol Market Forecast and Analysis
7.6. PYRAZINAMIDE
7.6.1. Overview
7.6.2. Pyrazinamide Market Forecast and Analysis
7.7. FLUOROQUINOLONES
7.7.1. Overview
7.7.2. Fluoroquinolones Market Forecast and Analysis
7.8. AMINOGLYCOSIDES
7.8.1. Overview
7.8.2. Aminoglycosides Market Forecast and Analysis
7.9. OTHERS
7.9.1. Overview
7.9.2. Others Market Forecast and Analysis
8. ANTI-TUBERCULOSIS THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - END USER
8.1. OVERVIEW
8.2. END USER MARKET FORECASTS AND ANALYSIS
8.3. HOSPITALS AND CLINICS
8.3.1. Overview
8.3.2. Hospitals and Clinics Market Forecast and Analysis
8.4. GOVERNMENT AGENCIES
8.4.1. Overview
8.4.2. Government Agencies Market Forecast and Analysis
8.5. NON PROFIT ORGANIZATIONS
8.5.1. Overview
8.5.2. Non Profit Organizations Market Forecast and Analysis
8.6. OTHERS
8.6.1. Overview
8.6.2. Others Market Forecast and Analysis
9. ANTI-TUBERCULOSIS THERAPEUTICS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Anti-Tuberculosis Therapeutics Market Overview
9.1.2 North America Anti-Tuberculosis Therapeutics Market Forecasts and Analysis
9.1.3 North America Anti-Tuberculosis Therapeutics Market Forecasts and Analysis - By Drug Class
9.1.4 North America Anti-Tuberculosis Therapeutics Market Forecasts and Analysis - By End User
9.1.5 North America Anti-Tuberculosis Therapeutics Market Forecasts and Analysis - By Countries
9.1.5.1 United States Anti-Tuberculosis Therapeutics Market
9.1.5.1.1 United States Anti-Tuberculosis Therapeutics Market by Drug Class
9.1.5.1.2 United States Anti-Tuberculosis Therapeutics Market by End User
9.1.5.2 Canada Anti-Tuberculosis Therapeutics Market
9.1.5.2.1 Canada Anti-Tuberculosis Therapeutics Market by Drug Class
9.1.5.2.2 Canada Anti-Tuberculosis Therapeutics Market by End User
9.1.5.3 Mexico Anti-Tuberculosis Therapeutics Market
9.1.5.3.1 Mexico Anti-Tuberculosis Therapeutics Market by Drug Class
9.1.5.3.2 Mexico Anti-Tuberculosis Therapeutics Market by End User
9.2. EUROPE
9.2.1 Europe Anti-Tuberculosis Therapeutics Market Overview
9.2.2 Europe Anti-Tuberculosis Therapeutics Market Forecasts and Analysis
9.2.3 Europe Anti-Tuberculosis Therapeutics Market Forecasts and Analysis - By Drug Class
9.2.4 Europe Anti-Tuberculosis Therapeutics Market Forecasts and Analysis - By End User
9.2.5 Europe Anti-Tuberculosis Therapeutics Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Anti-Tuberculosis Therapeutics Market
9.2.5.1.1 Germany Anti-Tuberculosis Therapeutics Market by Drug Class
9.2.5.1.2 Germany Anti-Tuberculosis Therapeutics Market by End User
9.2.5.2 France Anti-Tuberculosis Therapeutics Market
9.2.5.2.1 France Anti-Tuberculosis Therapeutics Market by Drug Class
9.2.5.2.2 France Anti-Tuberculosis Therapeutics Market by End User
9.2.5.3 Italy Anti-Tuberculosis Therapeutics Market
9.2.5.3.1 Italy Anti-Tuberculosis Therapeutics Market by Drug Class
9.2.5.3.2 Italy Anti-Tuberculosis Therapeutics Market by End User
9.2.5.4 Spain Anti-Tuberculosis Therapeutics Market
9.2.5.4.1 Spain Anti-Tuberculosis Therapeutics Market by Drug Class
9.2.5.4.2 Spain Anti-Tuberculosis Therapeutics Market by End User
9.2.5.5 United Kingdom Anti-Tuberculosis Therapeutics Market
9.2.5.5.1 United Kingdom Anti-Tuberculosis Therapeutics Market by Drug Class
9.2.5.5.2 United Kingdom Anti-Tuberculosis Therapeutics Market by End User
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Anti-Tuberculosis Therapeutics Market Overview
9.3.2 Asia-Pacific Anti-Tuberculosis Therapeutics Market Forecasts and Analysis
9.3.3 Asia-Pacific Anti-Tuberculosis Therapeutics Market Forecasts and Analysis - By Drug Class
9.3.4 Asia-Pacific Anti-Tuberculosis Therapeutics Market Forecasts and Analysis - By End User
9.3.5 Asia-Pacific Anti-Tuberculosis Therapeutics Market Forecasts and Analysis - By Countries
9.3.5.1 China Anti-Tuberculosis Therapeutics Market
9.3.5.1.1 China Anti-Tuberculosis Therapeutics Market by Drug Class
9.3.5.1.2 China Anti-Tuberculosis Therapeutics Market by End User
9.3.5.2 India Anti-Tuberculosis Therapeutics Market
9.3.5.2.1 India Anti-Tuberculosis Therapeutics Market by Drug Class
9.3.5.2.2 India Anti-Tuberculosis Therapeutics Market by End User
9.3.5.3 Japan Anti-Tuberculosis Therapeutics Market
9.3.5.3.1 Japan Anti-Tuberculosis Therapeutics Market by Drug Class
9.3.5.3.2 Japan Anti-Tuberculosis Therapeutics Market by End User
9.3.5.4 South Korea Anti-Tuberculosis Therapeutics Market
9.3.5.4.1 South Korea Anti-Tuberculosis Therapeutics Market by Drug Class
9.3.5.4.2 South Korea Anti-Tuberculosis Therapeutics Market by End User
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Anti-Tuberculosis Therapeutics Market Overview
9.4.2 Middle East and Africa Anti-Tuberculosis Therapeutics Market Forecasts and Analysis
9.4.3 Middle East and Africa Anti-Tuberculosis Therapeutics Market Forecasts and Analysis - By Drug Class
9.4.4 Middle East and Africa Anti-Tuberculosis Therapeutics Market Forecasts and Analysis - By End User
9.4.5 Middle East and Africa Anti-Tuberculosis Therapeutics Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Anti-Tuberculosis Therapeutics Market
9.4.5.1.1 South Africa Anti-Tuberculosis Therapeutics Market by Drug Class
9.4.5.1.2 South Africa Anti-Tuberculosis Therapeutics Market by End User
9.4.5.2 Saudi Arabia Anti-Tuberculosis Therapeutics Market
9.4.5.2.1 Saudi Arabia Anti-Tuberculosis Therapeutics Market by Drug Class
9.4.5.2.2 Saudi Arabia Anti-Tuberculosis Therapeutics Market by End User
9.4.5.3 U.A.E Anti-Tuberculosis Therapeutics Market
9.4.5.3.1 U.A.E Anti-Tuberculosis Therapeutics Market by Drug Class
9.4.5.3.2 U.A.E Anti-Tuberculosis Therapeutics Market by End User
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Anti-Tuberculosis Therapeutics Market Overview
9.5.2 South and Central America Anti-Tuberculosis Therapeutics Market Forecasts and Analysis
9.5.3 South and Central America Anti-Tuberculosis Therapeutics Market Forecasts and Analysis - By Drug Class
9.5.4 South and Central America Anti-Tuberculosis Therapeutics Market Forecasts and Analysis - By End User
9.5.5 South and Central America Anti-Tuberculosis Therapeutics Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Anti-Tuberculosis Therapeutics Market
9.5.5.1.1 Brazil Anti-Tuberculosis Therapeutics Market by Drug Class
9.5.5.1.2 Brazil Anti-Tuberculosis Therapeutics Market by End User
9.5.5.2 Argentina Anti-Tuberculosis Therapeutics Market
9.5.5.2.1 Argentina Anti-Tuberculosis Therapeutics Market by Drug Class
9.5.5.2.2 Argentina Anti-Tuberculosis Therapeutics Market by End User
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. ANTI-TUBERCULOSIS THERAPEUTICS MARKET, KEY COMPANY PROFILES
11.1. MACLEODS PHARMACEUTICALS LTD.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. OTSUKA PHARMACEUTICAL CO., LTD.
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. JOHNSON & JOHNSON SERVICES, INC.
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. PFIZER INC.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. LUPIN
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. NOVARTIS AG
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. ASTRAZENECA PLC
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. ELI LILLY AND COMPANY
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. GLAXOSMITHKLINE PLC
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. SANOFI
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

1. Macleods Pharmaceuticals Ltd.
2. Otsuka Pharmaceutical Co., Ltd.
3. Johnson & Johnson Services, Inc.
4. Pfizer Inc.
5. LUPIN
6. Novartis AG
7. AstraZeneca PLC
8. Eli Lilly And Company
9. GlaxoSmithKline Plc.
10. Sanofi
TIPRE00008533
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking